[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaccine-preventable-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaccine-preventable-diseases":157},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,84,111,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100638753","phase-4-maternal-immunization-with-tetanus-toxoid-reduced-diphtheria-toxoid-reduced-dose-2-g-recombinant-pertussis-vaccine-tdap2gen-and-its-effect-on-the-immune-response-in-thai-infants-up-to-15-18-months-old-100638753",false,"NCT07621341","Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months Old","Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response to Tetanus, Diphtheria and Pertussis in Thai Infants up to 15-18 Months Old: An Open-label, Randomized Controlled Trial","M-PRIME","Phase 1: Pregnant women\n\nInclusion Criteria:\n\n* Pregnant women aged 20 to 45 years\n* Healthy women in good general health\n* Gestational age between 20 and 32 weeks at enrollment\n* Singleton pregnancy\n* Low-risk, uncomplicated pregnancy as assessed by an obstetrician\n* No evidence of congenital anomalies identified on prenatal ultrasonographic screening\n* Willing to receive TdaP2gen vaccination and comply with collection of biological specimens as specified in the study protocol\n* Willing to allow their infant to receive either whole-cell pertussis-containing or acellular pertussis-containing combination vaccines according to the study randomization process, and to allow collection of biological specimens from the infant as specified in the study protocol\n* Able and willing to provide written informed consent prior to study participation\n\nExclusion Criteria:\n\n* Receipt of a tetanus-, diphtheria-, and chemical-detoxified pertussis-containing vaccine within 1 year prior to enrollment, or receipt of a tetanus-, diphtheria-, and genetic-detoxified pertussis-containing vaccine (TdaPgen) or genetic-detoxified acellular pertussis vaccine (aPgen) within 2 years prior to enrollment, including during the current pregnancy\n* History of laboratory-confirmed or clinically diagnosed pertussis infection within 1 year prior to enrollment\n* Presence of underlying medical conditions that may affect study outcomes, including but not limited to malignancy, autoimmune disease, immunodeficiency, epilepsy, hypertension, renal disease, or liver disease, as determined by the investigators\n* Pregnancy complications including hypertension (blood pressure \\>140\u002F90 mmHg with proteinuria, or \\>150\u002F100 mmHg regardless of proteinuria), current antihypertensive treatment, or preeclampsia\n* Endocrine disorders including hyperthyroidism, untreated hypothyroidism, or impaired glucose tolerance (e.g., type 1 or type 2 diabetes mellitus) diagnosed before or during pregnancy requiring treatment beyond dietary control\n* Severe or progressive neurological disorders, including epilepsy or a history of Guillain-Barré syndrome\n* Receipt of immunosuppressive agents, immunomodulatory agents, or high-dose systemic corticosteroids (\\>2 mg\u002Fkg\u002Fday, \\>20 mg\u002Fday, or equivalent) for more than 14 consecutive days within 6 months prior to enrollment\n* History of stillbirth, neonatal death, or recurrent spontaneous abortion (≥3 episodes).\n* Current medical or surgical treatment for prevention of preterm labor during the current pregnancy\n* Receipt of blood products, blood components, or immunoglobulins within 6 months prior to enrollment\n* Receipt of live attenuated vaccines within 3 months or any other vaccines within 28 days prior to enrollment\n* History of hypersensitivity or adverse reactions to study vaccines or vaccine components, or history of severe allergic reactions such as anaphylaxis to any vaccine\n* Behavioral, cognitive, or psychiatric conditions that, in the opinion of the investigator, may interfere with study participation or protocol compliance\n* History of smoking, alcohol abuse, or intravenous drug use that, in the opinion of the investigator, may interfere with study assessments or outcomes\n* Fever (body temperature ≥38.0°C or equivalent) within 72 hours prior to enrollment\n* Acute illness within 4 weeks prior to enrollment\n* Contraindications to intramuscular vaccination, including thrombocytopenia, coagulation disorders, hemophilia A or B, or use of anticoagulant therapy during pregnancy\n* Concurrent participation in another clinical study involving investigational vaccines or medications during participation in this study\n* Any medical or obstetric condition that, in the opinion of the study investigator, may interfere with study assessments or increase the risk to the mother or infant associated with study participation\n\nPhase 2: Infants\n\nInclusion Criteria:\n\n\\- All infants born to pregnant women enrolled in Phase 1 who received TdaP2gen vaccination during pregnancy will be eligible for enrollment to Phase 2 study\n\nExclusion Criteria:\n\n* Gestational age \\\u003C32 weeks (very preterm birth)\n* Birth weight \\\u003C1,500 grams (very low birth weight)\n* Presence of major congenital anomalies identified after birth, including congenital abnormalities associated with genetic disorders, congenital infections, or severe structural abnormalities involving major organ systems such as the central nervous system, cardiovascular system, respiratory system, hepatobiliary and gastrointestinal system, or genitourinary system\n* Presence of severe neonatal medical conditions that may affect immune responses to study vaccines, including but not limited to severe respiratory distress, severe bronchopulmonary dysplasia, hypoxic ischemic encephalopathy (HIE), severe intraventricular hemorrhage (IVH), severe sepsis, non-physiologic jaundice, neonatal autoimmune thrombocytopenia, neurological disorders such as neonatal convulsions, necrotizing enterocolitis, or intracranial hemorrhage\n* Presence of conditions associated with increased risk of serious adverse reactions to study vaccines\n* Any medical condition or circumstance that, in the opinion of the study investigator, may interfere with study assessments or increase the risk to the participant associated with study participation",true,"ALL","0 Days","45 Years",{"count":22,"type":23},320,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Pertussis remains a major global public health problem. In Thailand, pertussis vaccination is recommended during pregnancy at 20-32 weeks' gestation, together with routine childhood diphtheria-tetanus-pertussis vaccination administered as a primary series at 2, 4, and 6 months and booster doses at 18 months and 4-6 years of age.\n\nTdaP2gen, a newly developed combined tetanus, diphtheria, and recombinant genetically detoxified acellular pertussis vaccine containing 2 µg pertussis antigen, has shown favorable safety and non-inferior immunogenicity compared with existing pertussis vaccines. However, data on its use in pregnant women, transplacental antibody transfer, and potential immune interference in infants remain limited.\n\nThis study aims to evaluate the safety and immunogenicity of TdaP2gen in pregnant women, assess antibody transfer to newborns, and investigate immune responses to tetanus, diphtheria, and pertussis following primary and booster pertussis-containing vaccinations in infants and toddlers, including comparisons between whole-cell and acellular pertussis-containing vaccine schedules.",[29,30,31,32],"Pertussis","Diphtheria","Tetanus","Vaccine-Preventable Diseases",[34,35,36,37,38,39,40,41],"Safety","Immunogenicity","Immune interference","Pregnant women","Newborns","Infants and young children","Pertussis-containing vaccine","Genetically-detoxified recombinant acellular pertussis vaccine","NOT_YET_RECRUITING","2026-05-27",{"date":45,"type":46},"2026-06-02","ACTUAL",{"date":48,"type":23},"2026-05-26",{"date":50,"type":23},"2030-12-31",{"name":52,"class":53},"Chiang Mai University","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":24,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":54},"100514926","playing-game-to-learn-about-childrens-vaccine-project-100514926","NCT05984849","Playing Game to Learn About Children's Vaccine Project","A Pilot Randomized Controlled Study to Examine Feasibility and Preliminary Effectiveness of a Game-based Intervention in Promoting HPV Vaccination Among Vulnerable Youth to Prevent Cancers","Inclusion Criteria:\n\n* Child sample: (1) 11-14 years old, (2) speaks and reads English, (3) has never received any doses of the HPV vaccine, (4) is not currently enrolled in another project that involves HPV-related education, and (5) agrees and provides assent to participate in research activities.\n* Parent sample: (1) parent or legal guardian of the participating child, (2) speak and read English, (3) own a smartphone, (4) agree to receive email and text messages, (5) is not currently enrolled in another project that involves HPV-related education, and (6) agree and provide consent to participate in research activities.\n\nExclusion Criteria: Individuals who do not meet inclusion criteria or refuse to provide consent\u002Fassent.","11 Years","14 Years",{"count":65,"type":23},180,[67],"NA","This proposed study aims to conduct timely research that promotes vaccine confidence and vaccination of one strongly recommended vaccine with suboptimal uptake rates: Human papillomavirus (HPV) in vulnerable and underserved youth aged 11-14.",[70,32],"HPV",[72,73],"adolescent","game intervention","RECRUITING","2026-05-18",{"date":77,"type":46},"2026-05-20",{"date":79,"type":46},"2025-10-27",{"date":81,"type":23},"2027-08-31",{"name":83,"class":53},"Michigan State University",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":17,"sex":18,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100526669","phase-1-safety-and-immunogenicity-of-cvi-vzv-001-for-prevention-of-herpes-zoster-in-healthy-adults-age-50-years-and-above-100526669","NCT06137755","Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above","A Multicenter, Active-controlled, Open-label Phase I Study to Assess Safety and Tolerability and to Explore Immunogenicity of CVI-VZV-001 Vaccine in Healthy Adults Aged 50 to 64 Years","Inclusion Criteria:\n\n1. Healthy adults over 50 years old and under 65 years old\n2. Those who voluntarily decided to participate and gave written consent after hearing and understanding the detailed explanation of this clinical trial\n3. Women with childbearing potential and those who agree to use the contraceptive method\\* permitted up to 3 months after the final vaccination for clinical trials (\\* Combination use such as hormonal contraception, intrathyroidal device (IUD (Intrauterine device) or IUS (Intrauterine system), vasectomy, tubal stomy, double block method (cervical cap, use with contraceptive diaphragm)\n4. Women of childbearing potential with negative result at pregnancy test before vaccination for clinical trials.\n\nExclusion Criteria:\n\n1. Those with a past history of shingles before screening\n2. Persons with hypersensitivity to clinical investigational products or the ingredients of clinical investigational products\n3. Those with thrombocytopenia or other coagulation disorders who should not receive intramuscular injections, or those receiving anticoagulant therapy\\*\n\n   \\*Anticoagulant therapy: Continuous use of anticoagulants such as coumarin\u002Fwarfarin or new oral anticoagulants\u002Fantiplatelet agents\n4. Those with a history of immune dysfunction, including immunodeficiency disease\n5. Those suffering from chronic underlying diseases that, in the opinion of the investigator, may interfere with the progress and completion of this clinical trial\n6. Those with a history of excessive alcohol consumption or drug addiction\n7. Persons with a history of serious adverse events, allergies or hypersensitivity reactions related to vaccination (e.g. anaphylaxis, Guillain-Barré Syndrome)\n8. Those with a history of malignant tumor\n9. Those who developed a fever (tympanic membrane temperature of 38.0°C or higher) within 3 days prior to the first vaccination of clinical investigational product, suffered from a febrile illness on the day of vaccination, or suffered from a disease with moderate or more acute symptoms (mild illness without fever) (e.g. If you have mild diarrhoea, mild upper respiratory infection), you can participate in the clinical trial at the discretion of the investigator.)\n10. Those who have received chickenpox or shingles vaccine before screening\n11. Those who have participated in past chickenpox or shingles vaccine clinical trials\n12. Those who have been vaccinated with another vaccine within 4 weeks prior to the first injection of the investigational product, or who plan to be vaccinated with another vaccine by 48 weeks after the second injection of the investigational product (however, seasonal or pandemic flu) (inactivated and subunit influenza vaccine and COVID-19 vaccine for prevention of flu) are contraindicated only within 2 weeks before and after vaccination of each clinical investigational product)\n13. Those who have received blood products or immunoglobulin within 3 months prior to receiving the first clinical investigational product, or those who plan to administer it during the clinical trial period\n14. Those who have received immunosuppressants, immunomodulating drugs, other cytotoxic anticancer drugs that may affect immunity, or have experienced radiation therapy within 6 months prior to receiving the first clinical investigational product.\n15. Those who have experienced systemic steroid administration within 3 months prior to receiving the first clinical investigation drug (those who are taking a dose of 20 mg\u002Fday or more based on prednisone continuously for more than 2 weeks) However, topical, inhalation ( Inhaled, intranasal, intra-articular, and intra-bursal administration is permitted regardless of dosage.\n16. Organ transplant or hematopoietic stem cell transplant patients\n17. Those with positive virus test results (HCV Ab, HBsAg, HIV Ab) performed at screening\n18. Persons with clinically significant abnormalities in tests performed during screening (clinical laboratory tests, electrocardiogram, vital signs, etc.)\n19. Those taking antiviral drugs (Acyclovir, Valacyclovir, Famciclovir, Ganciclovir, etc.) known to be effective against varicella-zoster virus at the time of screening (topical use of antiviral drugs is permitted)\n20. Those with a history of active tuberculosis\n21. A person who has received another clinical investigational product or applied a clinical trial medical device within 6 months before participating in a clinical trial\n22. Pregnant or lactating women\n23. If the investigator determines that the subject is unsuitable for this clinical trial for other reasons","50 Years","64 Years",{"count":94,"type":23},32,[96],"PHASE1","The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.",[32,99],"Herpes Zoster","2024-11-16",{"date":102,"type":46},"2024-11-19",{"date":104,"type":46},"2023-03-15",{"date":106,"type":23},"2025-03-21",{"name":108,"class":109},"CHA Vaccine Institute Co., Ltd.","INDUSTRY",2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":18,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":24,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":54},"100522909","phase-3-a-phase--clinical-study-to-evaluate-protective-efficacy-and-safety-of-a-recombinant-herpes-zoster-vaccine-100522909","NCT06088745","A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety, and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Subjects Aged 40 Years and Older","Inclusion Criteria:\n\n* Males and females able to provide legal identity certificate, aged ≥ 40 years inclusive at the time of signing the ICF;\n* Able to understand the study procedures, voluntarily agree to participate in the study, and sign the ICF;\n* Female subjects are not pregnant or lactating. Female subjects with childbearing potential should take reliable contraceptive measures, and have no pregnancy and fertility plan within 7 months;\n* Axillary temperature ≤ 37.0℃ on the day of enrollment;\n* Able to attend all scheduled follow-up visits and able to comply with protocol requirements;\n\nExclusion Criteria:\n\n* Subjects who have had herpes zoster within the previous 5 years;\n* Previous vaccination against varicella or shingles (including use of a registered product or participation in a clinical trial of varicella or shingles vaccine);\n* Hypersensitivity to any of the components of the test vaccine: or prior hypersensitivity to any recombinant vaccine of CHO cell origin \\[e.g., recombinant hepatitis B vaccine (CHO cell)\\], polysorbate, etc.; or prior history of severe allergy\\* to any of the vaccinations;\n\n  \\*Severe allergies: anaphylaxis, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, localized anaphylactic necrotic reaction (Arthus reaction), severe urticaria.\n* Developed immunodeficiency diseases (congenital or acquired immunodeficiency diseases, human immunodeficiency virus infection) or received immunosuppressive\u002Fcytotoxic treatments (cancer chemotherapy, organ transplantation, or treatment planned during a clinical trial in the 6 months prior to vaccination);\n* Receiving immunosuppressive therapy (e.g., long-term systemic glucocorticoid application for ≥14 days at a dose of ≥2 mg\u002Fkg\u002Fday or ≥20 mg\u002Fday of prednisone or prednisone-equivalent dose) within 3 months prior to vaccination or within 1 month after the planned full course of immunization；\n* Received an inactivated or recombinant vaccine or mRNA vaccine within 14 days or any live attenuated vaccine within 28 days prior to vaccination;\n* Subjects who are suffering from an acute illness or are in the acute exacerbation phase of a chronic disease within 3 days prior to vaccination;\n* History of asplenia or functional asplenia, and asplenia or splenectomy due to any condition;\n* Treatment with blood products or globulins within 3 months prior to enrollment, or planned use of such products within 2 months of vaccination;\n* Participating in other clinical studies of investigational or un-registered products (drugs, vaccines or devices, etc.), or planning to participate in other clinical studies before the end of this clinical study;\n* Significant underlying medical conditions that, in the opinion of the investigator, may prevent completion of the trial (e.g., life-threatening disease that may limit survival to less than 4 years) or any other condition","40 Years",{"count":120,"type":23},4,[122],"PHASE3","This clinical trial is to study protective efficacy and safety of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd. It is a phase Ⅲ, randomized, double-blind, placebo-controlled in healthy people aged 40 years and older. The study is to protect adults against shingles (herpes zoster \u002F varicella zoster virus(VZV)). There will be about 26000 participators who will receive two-dose injection at the upper arm.\n\nLZ901 vaccine is made up of a tetramer of VZV glycoprotein E (VZV gE-Fc) and adsorbed with aluminum hydroxide adjuvant. This adjuvant can raise the immune response to a lot of antigens. It is the most widely used and safe adjuvant in various types of vaccines worldwide.",[32,99],"2023-10-12",{"date":127,"type":46},"2023-10-18",{"date":129,"type":46},"2023-09-28",{"date":131,"type":23},"2026-12-31",{"name":133,"class":53},"Beijing Luzhu Biotechnology Co., Ltd.",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100520285","animal-bite-victims-seeking-medical-services-at-concerned-hospitals-100520285","NCT06054581","Animal Bite Victims Seeking Medical Services at Concerned Hospitals","A Study of Animal Bite Among Victims Seeking Medical Services at the Concerned Hospitals in Assiut City","Inclusion Criteria:\n\n* victims recently exposed to bite by any animal causing rabies\n\nExclusion Criteria:\n\n* other types of animal bites",{"count":142,"type":23},662,"OBSERVATIONAL","The goal of this observational study is to study the magnitude of the animal bite problem during one year ,to determine the percentage of compliance for full PEP doses and factors affecting the health seeking behavior among these victims.\n\nTo assess the management of the wound (first aid management done by the patient and in the hospital).\n\nParticipants will be asked to answer a questionnaire consisting of five parts and followed for completing their anti-rabies vaccination schedule.",[32],[147],"animal bite, vaccine compliance","2023-09-20",{"date":150,"type":46},"2023-09-26",{"date":152,"type":23},"2024-01",{"date":154,"type":23},"2028-12",{"name":156,"class":53},"Assiut University","Vaccine Preventable Diseases"]